CN101269047A - Tolterodine tartrate sustained-release dropping pill and preparation method thereof - Google Patents
Tolterodine tartrate sustained-release dropping pill and preparation method thereof Download PDFInfo
- Publication number
- CN101269047A CN101269047A CNA200810112403XA CN200810112403A CN101269047A CN 101269047 A CN101269047 A CN 101269047A CN A200810112403X A CNA200810112403X A CN A200810112403XA CN 200810112403 A CN200810112403 A CN 200810112403A CN 101269047 A CN101269047 A CN 101269047A
- Authority
- CN
- China
- Prior art keywords
- framework material
- tolterodine tartrate
- preparation
- stabilizing agent
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug compound for treating urinary incontinence, frequency of micturition and urgency of micturition due to bladder stimulation and particularly relates to a prepared sustained-release tolterodine tartrate dropping pill adopting tolterodine tartrate as the ingredient. The drug compound aims to supplement the deficiency of the prior art and provide a sustained-release tolterodine tartrate dropping pill formulation. The sustained-release tolterodine tartrate dropping pill is prepared by adding stabilize Vitamin A and hydrophobic framework ingredients to the ingredients adopted by the prior art, thereby overcoming the defects in the prior art effectively, guaranteeing no occurrence of an obvious change related to the substance content for the drug during the effective storage period and having the advantages of full release, controllable release time and high bioavailability simultaneously. The sustained-release tolterodine tartrate dropping pill is suitable for clinical and family use.
Description
Technical field
The invention belongs to slow release pharmaceutical technology field, be specifically related to a kind of urinary incontinence that causes because of bladder irritation, the pharmaceutical composition of symptom such as frequent micturition and urgent micturition particularly is a kind of tartaric acid toterodine slow released drip pill medicine that feedstock production forms with the Tolterodine tartrate.
Background technology
Tolterodine tartrate (tolterodineL-tartrate), chemistry (R)-N by name, N-diisopropyl-3-(2-hydroxy-5-methyl base phenyl)-3-phenylpropylamine L (+)-tartrate.Be novel muscarinic receptor antagonist, have the favorable tissue selectivity, clinically be used for the treatment of urgent micturition, frequent micturition, urge incontinence.Clinical research shows: Tolterodine tartrate can significantly reduce the frequency of urinating and the attack times of urinary incontinence, characteristics such as rapid-action, that acting duration is long, side effect is little.
Following is Tolterodine tartrate sheet description:
[another name] Tolterodine tartrate sheet,
[English name]: Tolterodine Tartrate Tablets.
[this product main component]: (R)-N, N-diisopropyl-3-(2-hydroxy-5-methyl base phenyl)-3-phenylpropylamine L (+)-tartrate.
[character] this product is the white film garment piece, removes whitening color behind the film-coat.
[pharmacological action] this product is used to alleviate frequent micturition, urgent micturition and the urgent urinary incontinence symptom due to the bladder excessive activities, is competitive M nachr antagonist.This product is oral after liver metabolism has become the active metabolite 5-hydroxymethyl derivative of main pharmacological, and its cholinolytic is active close with this product.Both all have high selectivity to the M cholinoceptor, and are very weak to the effect or the affinity of the receptor of other neurotransmitteies and potential cell target spot (as calcium channel).Can promptly absorb after this product is oral, absorbance is greater than 77%.The absorption of food, the difference of age and sex need not adjusted dosage.The oral 1-4mg of this product, maximum plasma concentration (Cmax) and area under the drug-time curve (AUC) are linear with dosage.Behind oral this product 2mg, reach peak value blood drug level about 2.5h, Cmax is 2.5 μ g/L, and AUC is 11.8 μ g/Lh.The blood drug level of 5-methylol active metabolite (DD01) is extremely similar to this product original shape, and Cmax is 2.2 μ g/L, and AUC is 12.1 μ g/Lh.This product and plasma protein binding rate are higher, the concentration average out to 3.7% ± 0.13% of free tolterodine.DD01 and plasma protein binding rate are not high, the concentration average out to 36% ± 4.0% of free DD01.This product and its metabolite DD01 are respectively 0.6 and 0.8 at the ratio of blood and blood plasma.The distribution volume of intravenous injection this product 1.28mg is 113 ± 26.7L.
[indication] this product is applicable to the treatment because of the frequent micturition that the bladder excessive excitement causes, urgent micturition or urgent urinary incontinence symptom.
[usage and consumption] initial recommended dose is each 2mg, every day secondary.According to patient's reaction and tolerance degree, dosage can be lowered to each 1mg, every day secondary.For hepatic insufficiency or the patient who is taking CYP3A4 inhibitor (seeing drug interaction), recommended dose is each 1mg, every day secondary.
[contraindication]
Urine retention, stomach be defaulted, without the narrow angle type glaucoma patient forbidding of control.
Having confirmed has anaphylactoid patient's forbidding to this product.
Myasthenia gravis patient, serious patients of ulcerative colitis, toxic megacolon patient are forbidden.
The side effect of [untoward reaction] this product generally can tolerate, and can disappear after the drug withdrawal.This product can cause gently, the moderate anticholinergic effect, as xerostomia, dyspepsia and oligodacrya.
" common ": 1. autonomic nervous system: xerostomia; (＞1/100) .2. gastronintestinal system: dyspepsia, constipation, stomachache, flatulence, vomiting; 3. general: headache; The eye: xerophthalmia; 5. skin: xerosis cutis; 6. spiritual: drowsy, neurotic; 7. central nervous system: paraesthesia.
" not really common ": 1. autonomic nervous system: regulate imbalance; (＜1/100) is general 2.: chest pain.
" rarely ": 1. general: anaphylaxis; (1/1000) 2. urinary system: urine retention; 3. central nervous system: confusion.
[points for attention]
Take this product and may cause blurred vision, steering vehicle during the medication, machining and carrying out the dangerous operation person should be noted that.
Liver function is low patient obviously, and each dosage must not surpass half sheet (1mg).
The patient of poor kidney, autonomy sacred disease patient, the careful this product of using of ceasma hernia patient.
Since the risk of urine retention, the careful patient who is used for bladder outlet obstruction (BOO) of this product; Because the defaulted risk of stomach, also carefully be used to suffer from the gastrointestinal tract obstructive disease, as the patient of pyloric stenosis;
Still do not have the children experience, do not recommend the child to use.
The careful this product of using of anemia of pregnant woman is taken this product and should be stopped suckling between age of sucking.
[drug interaction]
Can strengthen therapeutical effect when merging administration but also strengthen untoward reaction with the medicine of other tool cholinolytic effect.Otherwise agonists of muscarinic receptors can reduce the curative effect of this product.
Other medicines maybe can suppress the cytochrome activity because of need cytochrome P 4502 D 6 (CYP 2D6) or CYP3A4 carry out metabolism, thus may with the interaction on this product generation pharmacokinetics.As merging with fluoxetine (fluoxetine is the potent inhibitor of CYP2D6, and fluoxetine is metabolised to the inhibitor that the demethyl fluoxetine is CYP3A4) that administration can slightly increase non-binding type tolterodine and 5-methylol metabolite amount thereof but this does not cause the interaction of obvious clinical meaning.The CYP3A4 inhibitor such as the macrolide antibiotics (erythromycin and clarithromycin) of usefulness are pretended in use, antifungal agent (ketoconazole, miconazole, Itraconazole) should be very careful as merging.
Clinical studies show this product and warfarin or oral contraceptive (Levonorgestrel Ethinylestradiol) merge administration does not have interaction.
The clinical research result shows that also this product has suppressed the activity of CYP2D6,2C19,3A4 or 1A2.
[processing of over administration]
Giving volunteer's maximal dose is that single agent gives Tolterodine tartrate 12.8mg, and its serious adverse effects is to regulate imbalance and dysuria.In the excessive incident of this this product with gastric lavage with give active carbon and treat.
Treatment to symptom is as follows: serious maincenter anticholinergic effect (as hallucination, serious excitement) is treated with physostigmine.
Twitch or significant excited (benzodizepines) stable class Drug therapy of using.
Respiratory insufficiency: treat with the artificial respiration.
Tachycardia: treat with beta-blocker.
Urine retention: treat with plug in catheter.
Mydriasis: pilocarpine eye drip or patient placed the darkroom.
14 in [specification] every box, every 2mg.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, medicining times is many, drug release time is uncontrollable, problems such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.In addition, conventional peroral dosage form is as tablet, capsule, granule (electuary) etc., in preparation process because the technology of granulation is arranged, therefore can produce bigger dust pollution, can staff's health be worked the mischief to a certain extent, also can cause certain pollution simultaneously to environment.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Summary of the invention
The objective of the invention is to replenish the deficiencies in the prior art, a kind of tartaric acid toterodine slow released drip pill preparation is provided.Tartaric acid toterodine slow released drip pill involved in the present invention, be in the component that adopts in prior art, stabilizing agent vitamin A and hydrophobicity framework material have been added, effectively overcome the defective of prior art, guarantee that the obvious change of its related substances can not take place medicine in effective storage period, it is abundant that the while also has release, drug release time is controlled, medicining times is few, the advantage that bioavailability is high, and suitable clinical and family uses.
Be prepared by the following technical solutions, can obtain tartaric acid toterodine slow released drip pill involved in the present invention:
[composition]
1. raw material: Tolterodine tartrate
1.1 common name: tolterodine-tartrate
1.2 English name: Tolterodine-tartrate
1.3 chemical name: (R)-N, N-diisopropyl-3-(2-hydroxy-5-methyl base phenyl)-3-phenylpropylamine L (+)-tartrate.
1.4 molecular formula: C
22H
31NO.C
4H
6O
6
1.5 molecular weight: 475.6
2. substrate: hydrophilic framework material and hydrophobicity framework material
2.1 hydrophilic framework material: the mixture of one or more in polyethylene glycol 1500, Macrogol 4000, polyethylene glycol 6000, the above-mentioned pharmaceutically suitable carrier of microcrystalline Cellulose;
2.2 hydrophobicity framework material: the mixture of one or more in stearic acid, cohune eleostearic acid, the above-mentioned pharmaceutically suitable carrier of glyceryl monostearate;
3. stabilizing agent: form by vitamin A.
[preparation method]
1. component constitutes: calculate according to percentage by weight, tartaric acid toterodine slow released drip pill involved in the present invention is made up of substrate and the 0.5-5% stabilizing agent of 10-40% Tolterodine tartrate and 60-90%, and substrate comprises 40-80% hydrophilic framework material and 10-30% hydrophobic framework material.
2. preparation method: take by weighing described hydrophilic framework material and hydrophobic framework material earlier, place the heating container internal heating and stir and make it to dissolve, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after stabilizing agent stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills condensed fluid, take out after being shaped, promptly.
3. in the above-mentioned preparation method, the temperature during described heating and melting is 55 ℃～85 ℃.
4. in the above-mentioned preparation method, described condensed fluid is greater than the dimethicone of 150# or liquid paraffin.
5. in the above-mentioned preparation method, the temperature on described condensed fluid top is 20 ℃～30 ℃, and the temperature of bottom is-4 ℃～10 ℃.
[beneficial effect]
Tolterodine tartrate (tolterodineL-tartrate), chemistry (R)-N by name, N-diisopropyl-3-(2-hydroxy-5-methyl base phenyl)-3-phenylpropylamine L (+)-tartrate.Be novel muscarinic receptor antagonist, have the favorable tissue selectivity, clinically be used for the treatment of urgent micturition, frequent micturition, urge incontinence.Clinical research shows: Tolterodine tartrate can significantly reduce the frequency of urinating and the attack times of urinary incontinence, characteristics such as rapid-action, that acting duration is long, side effect is little.On the existing market Tolterodine tartrate tablet oral formulations is arranged.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, medicining times is many, drug release time is uncontrollable, problems such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.In addition, conventional peroral dosage form is as tablet, capsule, granule (electuary) etc., in preparation process because the technology of granulation is arranged, therefore can produce bigger dust pollution, can staff's health be worked the mischief to a certain extent, also can cause certain pollution simultaneously to environment.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
The objective of the invention is to replenish the deficiencies in the prior art, a kind of tartaric acid toterodine slow released drip pill preparation is provided.Tartaric acid toterodine slow released drip pill involved in the present invention, be in the component that adopts in prior art, stabilizing agent vitamin A and hydrophobicity framework material have been added, effectively overcome the defective of prior art, guarantee that the obvious change of its related substances can not take place in effective storage period medicine, it is abundant that the while also has release, and drug release time is controlled, the advantage that bioavailability is high, suitable clinical and family uses.
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of tartaric acid toterodine slow released drip pill of the present invention.
First group:
In gross weight 100g, take by weighing substrate PEG400040%, PEG600010%, PEG150010%, stearic acid 11%, glyceryl monostearate 17%, stabilizing agent vitamin A 2%, raw material Tolterodine tartrate 10%; Substrate is made it to dissolve in placing the heating container internal heating and stirring, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after the stabilizing agent vitamin A stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills dimethicone, wherein, temperature during heating and melting is 55 ℃, and the temperature on condensed fluid top is 20 ℃, and the temperature of bottom is-4 ℃; The back taking-up is shaped.
Products obtained therefrom, 2 hours cumulative release percentage rate are that 34～56%, 6 hours cumulative release percentage rate are that 60～81%, 10 hours cumulative release percentage rate are 75～97%, continuous 3 months no significant change of related substance examination, roundness is better.
Second group:
In gross weight 100g, take by weighing substrate PEG400010%, PEG600020%, PEGl50030%, stearic acid 11%, glyceryl monostearate 8.5%, stabilizing agent vitamin A 0.5%, raw material Tolterodine tartrate 20%; Substrate is made it to dissolve in placing the heating container internal heating and stirring, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after the stabilizing agent vitamin A stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills liquid paraffin, wherein, temperature during heating and melting is 65 ℃, and the temperature on condensed fluid top is 30 ℃, and the temperature of bottom is 0 ℃; The back taking-up is shaped.
Products obtained therefrom, 2 hours cumulative release percentage rate are that 45%～65%, 6 hours cumulative release percentage rate are that 73～92%, 10 hours cumulative release percentage rate are 87～98%, continuous 3 months no significant change of related substance examination, roundness is better.
The 3rd group:
In gross weight 100g, take by weighing substrate microcrystalline Cellulose 10%, PEG600010%, PEG150020%, stearic acid 10%, cohune eleostearic acid 7%, stabilizing agent vitamin A 3%, raw material Tolterodine tartrate 40%; Substrate is made it to dissolve in placing the heating container internal heating and stirring, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after the stabilizing agent vitamin A stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills dimethicone, wherein, temperature during heating and melting is 75 ℃, and the temperature on condensed fluid top is 20 ℃, and the temperature of bottom is 0 ℃; The back taking-up is shaped.
Products obtained therefrom, 2 hours cumulative release percentage rate are that 41%～54%, 6 hours cumulative release percentage rate are that 62～80%, 10 hours cumulative release percentage rate are 75～93%, continuous 3 months no significant change of related substance examination, roundness is better.
The 4th group:
In gross weight 100g, take by weighing substrate microcrystalline Cellulose 10%, PEG600015%, PEG1000030%, glyceryl monostearate 2%, cohune eleostearic acid 8%, stabilizing agent vitamin A 5%, raw material Tolterodine tartrate 30%; Substrate is made it to dissolve in placing the heating container internal heating and stirring, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after the stabilizing agent vitamin A stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills dimethicone, wherein, temperature during heating and melting is 85 ℃, and the temperature on condensed fluid top is 30 ℃, and the temperature of bottom is 5 ℃; The back taking-up is shaped.
Products obtained therefrom, 2h cumulative release percentage rate is 37%～56%, and 6h cumulative release percentage rate is 62～84%, and 10h cumulative release percentage rate is 76～96%,, continuous 3 months no significant change of related substance examination, roundness is better.
The 5th group:
In gross weight 100g, take by weighing substrate microcrystalline Cellulose 10%, PEG400010%, PEG600030%, stearic acid 5%, glyceryl monostearate 3%, cohune eleostearic acid 10%, stabilizing agent dehydroretinol %, raw material Tolterodine tartrate 30%; Substrate is made it to dissolve in placing the heating container internal heating and stirring, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after the stabilizing agent vitamin A stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills dimethicone, wherein, temperature during heating and melting is 65 ℃, and the temperature on condensed fluid top is 20 ℃, and the temperature of bottom is 4 ℃; The back taking-up is shaped.
Products obtained therefrom, 2h cumulative release percentage rate is 40%～62%, and 6h cumulative release percentage rate is 67～85%, and 10h cumulative release percentage rate is 76～95%, continuous 3 months no significant change of related substance examination, roundness is better.
The 6th group:
In gross weight 100g, take by weighing substrate microcrystalline Cellulose 10%, PEG400020%, PEG600020%, PEG150020%, stearic acid 11%, glyceryl monostearate 7%, stabilizing agent vitamin A 2%, raw material Tolterodine tartrate 10%; Substrate is made it to dissolve in placing the heating container internal heating and stirring, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after the stabilizing agent vitamin A stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills dimethicone, wherein, temperature during heating and melting is 70 ℃, and the temperature on condensed fluid top is 30 ℃, and the temperature of bottom is 0 ℃; The back taking-up is shaped.
Products obtained therefrom, 2h cumulative release percentage rate is 43%～61%, and 6h cumulative release percentage rate is 71～88%, and 10h cumulative release percentage rate is 82～93%, continuous 3 months no significant change of related substance examination, roundness is better.
Claims (5)
1. urinary incontinence that causes because of bladder irritation, the pharmaceutical composition of symptom such as frequent micturition and urgent micturition, be particularly related to the Tolterodine tartrate is raw material, with being prepared from by certain component formation, wherein as the hydrophilic framework material of substrate and the pharmaceutically suitable carrier and the stabilizing agent of hydrophobicity framework material:
1.1. described substrate is made up of hydrophilic framework material and hydrophobicity framework material;
1.1.1 described hydrophilic framework material is by one or more the mixture in polyethylene glycol 1500, Macrogol 4000, polyethylene glycol 6000, the above-mentioned pharmaceutically suitable carrier of microcrystalline Cellulose;
1.1.2 described hydrophobicity framework material is by one or more the mixture in stearic acid, cohune eleostearic acid, the above-mentioned pharmaceutically suitable carrier of glyceryl monostearate;
1.2 described stabilizing agent is made up of vitamin A;
1.3 described component constitutes: calculate according to percentage by weight, tartaric acid toterodine slow released drip pill involved in the present invention is made up of substrate and the 0.5-5% stabilizing agent of 10-40% Tolterodine tartrate and 60-90%, and substrate comprises 40-80% hydrophilic framework material and 10-30% hydrophobicity framework material.
2. according to the preparation method of the described tartaric acid toterodine slow released drip pill of claim 1, it is characterized in that by following method preparation:
Take by weighing described hydrophilic framework material and hydrophobic framework material earlier, place the heating container internal heating and stir and make it to dissolve, the Tolterodine tartrate that adds corresponding proportion, fully stir, add again after stabilizing agent stirs, under heat-retaining condition, the medicinal liquid of fusion or mixing is splashed in the condensation column that fills condensed fluid, take out after being shaped, promptly.
3. according to the described preparation method of claim 2, the temperature when it is characterized in that described heating and melting is 55 ℃～85 ℃.
4. according to the described preparation method of claim 2, it is characterized in that described condensed fluid is dimethicone or the liquid paraffin greater than 150#.
5. according to the described preparation method of claim 2, the temperature that it is characterized in that described condensed fluid top is 20 ℃～30 ℃, and the temperature of bottom is-4 ℃～10 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810112403XA CN101269047A (en) | 2008-05-23 | 2008-05-23 | Tolterodine tartrate sustained-release dropping pill and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810112403XA CN101269047A (en) | 2008-05-23 | 2008-05-23 | Tolterodine tartrate sustained-release dropping pill and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101269047A true CN101269047A (en) | 2008-09-24 |
Family
ID=40003438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810112403XA Pending CN101269047A (en) | 2008-05-23 | 2008-05-23 | Tolterodine tartrate sustained-release dropping pill and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101269047A (en) |
-
2008
- 2008-05-23 CN CNA200810112403XA patent/CN101269047A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101926791A (en) | Phospholipid complex of silybin dihemisuccinate disodium and preparation method and application thereof | |
| CN101270072A (en) | Right-handed indobufen and use for preparing medicament | |
| CN102370730A (en) | Self-heated traditional Chinese medicine (TCM) emplastrum for treating osteoarthritis | |
| CN111557920A (en) | Lipoic acid-containing tablet and preparation method thereof | |
| CN1312157C (en) | Halogenated dihydroartemisine, preparation and use thereof | |
| CN100364533C (en) | Pyrolidone hydrochloride drip pill and its preparation method | |
| CN101269047A (en) | Tolterodine tartrate sustained-release dropping pill and preparation method thereof | |
| CN114432266B (en) | Stable cyclobenzaprine hydrochloride sustained-release capsule | |
| CN101269034A (en) | Nimesulide sustained-release dropping pill and preparation method thereof | |
| CN101269040A (en) | Pioglitazone hydrochloride sustained-release dropping pill and preparation method thereof | |
| CN101190185A (en) | Alkaline drug enteric preparation and preparation method thereof | |
| CN1264516C (en) | Ligustrazine phosphate dripping pill and preparation thereof | |
| CN107868009A (en) | A kind of metoprolol tartrate crystal and the pharmaceutical composition containing the crystal and preparation method thereof | |
| CN102579403B (en) | Duloxetine hydrochloride drug composition | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| CN101081227B (en) | Composition of diammonium glycyrrhizinate | |
| CN1636581A (en) | Safflower medicine composition and its prepn process and use | |
| CN1332669C (en) | Dripping pills for reducing swelling and easing pain and its preparing method | |
| CN102860997A (en) | Ondansetron oral cavity instant membrane capable of sheltering taste and preparation method thereof | |
| CN103041390A (en) | Melbine and ezetimibe combined composition medicament for treating nonalcoholic fatty liver disease | |
| CN111150735A (en) | Preparation for treating uric acid nephropathy | |
| CN100375612C (en) | Blood pressure lowering dripping pills with chryanthemum flower and pearl and its preparation process | |
| CN1172702C (en) | Sugar-free erigeron breviscapus granule and its prepn and application | |
| CN100542519C (en) | It with the Flos lupuli extractum pulmonary-toxin-clearing dropping pill of raw material and preparation method thereof | |
| CN100488509C (en) | Sildenafil citrate sublingual tablet and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080924 |